Sparian Biosciences Awarded $19 Million Five-Year NIH/ NIDA Grant to Fund Development of SBS-518 for Stimulant Use Disorder Through Phase 1 Clinical Development
Sparian Biosciences, Inc., a clinical-stage CNS-focused biopharmaceutical company, announced it has been awarded a $19 million, five-year grant to fund the development of SBS-518 from IND submission through Phase 1 clinical development.